Immunomonitoring Core

全面的免疫学评估对于改进疫苗至关重要。最近的研究 强调了在评估疫苗诱导的T细胞免疫应答中结合库分析的重要性。 功效免疫监测核心将提供信息（如T细胞表位、T细胞类型）， 反应，抗体滴度）和工具（如四聚体）进行研究所需的所有项目 通过专业知识和最先进的技术。免疫监测的主要目标 核心是：目的1：提供流感抗原特异性T细胞库（EpiMax）的最新分析。 流感抗原（H1 HA、M2和NP）特异性T细胞库将在 肽水平与从健康个体（来自样品核心），流感疫苗接种受试者， 和流感感染受试者（来自临床核心）。表位（CD 4+和CD 8 + T细胞）、类型和免疫原性。 将确定流感特异性T细胞应答的大小。目的2：提供以下方面的最新分析： 多个流感抗原特异性抗体升数（Ab Luminex）。流感抗原（H1 HA、H5 HA、M1、M2和 NP）特异性抗体将通过该研究所在Luminex平台上开发的测定法来测量。 目的3：提供流感抗原衍生肽/HLA I类或II类四聚体。的T细胞表位 将测试在EpiMax测定中鉴定的四聚体与HLA I类或II类分子的结合，并且四聚体将 在塞卡利博士的实验室里产生目的4：用鉴定的流感抗原表位进行细胞培养， 基因组免疫反应性谱。PBMC和鼻洗液样品的总体基因表达谱 与EpiMax鉴定的T细胞表位肽一起培养的细胞将与 微阵列核心。因此，免疫监测核心将广泛地与其他核心设施和所有 共同目标项目：粘膜疫苗的开发和生物标志物的建立 保护性免疫

Comprehensive immunological assessments are critical to improve vaccines. Recent studies have emphasized the importance of incorporating repertoire analysis in the assessment of vaccine-induced T cell efficacy. Immunomonitoring Core will provide the information (such as T cell epitopes, type of T cell responses, Ab titer) and tools (such as tetramers) required to perform the research in all the Projects through the expertise and state-of-the art technologies. The primary objectives of the Immunomonitoring Core are: AIM 1: To provide state-of-the-art analysis of the Flu antigen-specific T cell repertoires (EpiMax). T cell repertories specific for Flu antigens (H1 HA, M2, and NP) will be comprehensively analyzed at a peptide level with samples obtained from healthy individuals (from Sample Core), Flu-vaccinated subjects, and Flu-infected subjects (from Clinical Core). The epitopes (for CD4+ and CD8+ T cells), the type, and the magnitude of Flu-specific T cell responses will be determined. AIM 2: To provide state-of-art analysis of multiple Flu-antigen-specific antibody liters (Ab Luminex). Flu-antigen (H1HA, H5 HA, M1; M2, and NP)-specific antibodies will be measured by the assay developed at the Institute in a platform of Luminex. AIM 3: To provide Flu-antigen derived peptide/HLA class I or class II tetramers. The T cell epitopes identified in EpiMax assay will be tested for the binding to HLA class I or II molecules, and the tetramers will be generated at Dr. Sekaly's lab. AIM 4: To perform cell cultures with the identified Flu antigen epitopes for genomic Immunoreactivity profiles. Global gene expression profile of PBMCs and nasal wash samples cultured with the T cell epitope peptide identified with EpiMax will be analyzed in the collaboration with Microarray Core. Thus, Immunomonitoring Core will extensively interact with other Core facilities and all the Projects towards the common goals: development of mucosal vaccines, and establishment of biomarkers of protective immunity.